tiprankstipranks

UCB upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded UCB to Overweight from Neutral with a price target of EUR 200, up from EUR 150. The analyst expects an expected acceleration in Bimzelx growth driven by new indications and atopic dermatitis.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue